Investors looking for stocks that can triple their money found what they were looking for in the biotech industry quite a few times this year. Some of those rockets are going to keep climbing, but most will eventually fizzle out.
Surface Oncology (NASDAQ: SURF) and Replimmune (NASDAQ: REPL) are both clinical-stage drugmakers trying to find new ways to fight cancer. Both have more than tripled investors money this year, despite just beginning to show signs their experimental treatments might work.
Image source: Getty Images.
For further details see:
2 Biotech Stocks That Could Have Tripled Your Money This Year